Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Schalper KA (1), Carleton M (2), Zhou M (3), Chen T (3), Feng Y (3), Huang SP (3), Walsh AM (4), Baxi V (4), Pandya D (5), Baradet T (2), Locke D (2), Wu Q (5), Reilly TP (5), Phillips P (2), Nagineni V (6), Gianino N (6), Gu J (7), Zhao H (7), Perez-Gracia JL (8,9), Sanmamed MF (8,9,10,11), Melero I (12,13,14).
Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers.
Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor outcome in patients (n = 1,344) with advanced cancers treated with nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the importance of assessing serum IL-8 levels in identifying unfavorable tumor immunobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.
CITATION Nat Med. 2020 May;26(5):688-692. doi: 10.1038/s41591-020-0856-x. Epub 2020 May 11